Treatment
CAR-T cells clinical trials
We’re tracking 489 recruiting studies that include CAR-T cells, each written for real people, not researchers, below.
Recruiting studies
- NCT06614686RecruitingPhase 1
CAR-T therapy for advanced head and neck cancer
This study tests a new type of CAR-T cell therapy that targets a protein called Trop2 found on some head and neck cancer cells. It's for people who have tried standard treatments and need a new option.
ShanghaiAges 18–70 - NCT06106893RecruitingPhase 1/Phase 2
Study of CD19 CAR-γδT cells for active lupus
This trial is testing a new type of immune cell therapy (called CD19 universal CAR-γδT cells) for people with active lupus that hasn't been well controlled by standard treatments. The goal is to see if these specially designed cells can calm the immune system and reduce lupus symptoms.
Wuhan, HubeiAges 18–70 - NCT06665295Recruiting
THRIVE-CAR-T digital app for CAR-T patients
This trial tests a digital app to support patients receiving CAR-T therapy. It may help you track symptoms and communicate with your care team.
Boston, MassachusettsAges 18 years+ - NCT07085676RecruitingPhase 1
CAR-T cell therapy for autoimmune diseases that resist treatment
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
JerusalemAges 18–80 - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT07509450Recruiting
Fecal transplant study for CAR-T and stem cell transplant patients
This pilot study tests whether giving a fecal microbiota transplant before standard CAR-T therapy (for B-cell lymphoma) or reduced-intensity stem cell transplant (for AML or high-risk MDS) can improve treatment outcomes. It aims to see if restoring gut bacteria helps reduce complications.
Toronto, OntarioAges 18 years+ - NCT06247501RecruitingPhase 2
CAR-T therapy for children with B-cell ALL needing transplant
This study tests a new type of immune-cell therapy (called CAR-T cells) for children and young adults with a specific blood cancer (B-cell ALL) who need a stem cell transplant. The treatment uses a patient's own T-cells that are modified to find and kill cancer cells with the CD19 marker.
SeoulAges Up to 25 years - NCT07551349RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Kidney Cancer
This trial tests a new type of cell therapy (CAR-NK cells) designed to target kidney cancer that has spread or cannot be removed with surgery. The cells are engineered in the lab to recognize and attack cancer cells, and may help patients whose cancer has grown despite previous treatments.
Shenzhen, GuangdongAges 18 years+ - NCT06326021RecruitingPhase 1
CD33 CAR T for relapsed or refractory AML
This trial tests a new type of immune therapy called CAR T cells that target the CD33 protein on leukemia cells. It is for people with AML that has returned or not gone away after standard treatments, and who have a stem cell donor available for a transplant afterward.
Shanghai, Shanghai MunicipalityAges 1–70 - NCT07564401RecruitingPhase 1/Phase 2
CAR-T Cell Therapy for Advanced Lung Cancer
This study tests DJI136, a new type of cell therapy that trains your immune cells to fight small cell lung cancer. The therapy targets a protein called DLL3 found on cancer cells. It's designed for patients whose cancer has returned or progressed after initial chemotherapy and immunotherapy.
Lexington, KentuckyAges 18 years+ - NCT06610344Recruiting
BHB supplement with CAR-T for lymphoma
This study looks at adding a supplement called beta-hydroxybutyrate (BHB) to standard CAR-T therapy for people with large B-cell lymphoma. It may help improve how well the treatment works.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06709469RecruitingPhase 1
CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia
This trial tests a new CAR-T cell therapy for children, teens, and young adults with acute lymphoblastic leukemia that has not responded to standard treatment. The goal is to see if the therapy can put the leukemia into remission so the patient may then have a stem cell transplant.
Madrid, MadridAges Up to 30 years - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+ - NCT07052305RecruitingPhase 1
Testing NT-I7 after CAR T-cell therapy for large B-cell lymphoma
This trial tests whether a drug called NT-I7 (efineptakin alfa) can help people with large B-cell lymphoma who have already received a CAR T-cell treatment like Yescarta or Breyanzi. It aims to boost your immune system's recovery and improve outcomes.
St Louis, MissouriAges 18 years+ - NCT06365671RecruitingPhase 2
CAR-T therapy after stem cell transplant for high-risk B-cell lymphoma
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
ShanghaiAges 18 years+ - NCT07403812Recruiting
Checking thinking skills after CAR-T therapy
This study uses a simple iPad test to check for thinking problems that can happen after CAR-T cell therapy. It aims to catch these issues early so they can be managed better.
Boston, MassachusettsAges 18 years+ - NCT07744256RecruitingPhase 1/Phase 2
Dual-target CAR-NK cells for relapsed small cell lung cancer
This trial tests a new cell therapy that uses your own immune cells to attack cancer. It's for people with small cell lung cancer that has come back or not responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT06788964RecruitingPhase 2
Bridge therapy with loncastuximab and rituximab before CAR-T for lymphoma
This trial tests a two-drug combination (loncastuximab tesirine and rituximab) as a short-term "bridge" treatment for people with large B-cell lymphoma who are waiting to receive standard CAR-T cell therapy. The goal is to control the lymphoma before the CAR-T cells can be given.
Chapel Hill, North CarolinaAges 18 years+ - NCT07487597RecruitingEarly Phase 1
Engineered T cell therapy for ALPP-positive advanced solid tumors
This trial tests a new type of immune cell therapy designed to target and attack cancer cells that have a specific marker called ALPP. It is for people with advanced solid tumors who have not responded to or cannot have standard treatments.
Nanjing, JiangsuAges 18–70 - NCT07629596RecruitingEarly Phase 1
mRNA CAR-T therapy for severe lupus or autoimmune anemia
This early-stage trial tests a new mRNA-based therapy called Arnovie101 that trains your immune cells to fight lupus (SLE) or autoimmune hemolytic anemia (AIHA) that haven't improved with standard treatments. The therapy may help reduce disease activity and symptoms.
Beijing, Beijing MunicipalityAges 18–60 - NCT05472558RecruitingPhase 1
CAR-NK cell treatment for CD19-positive relapsed lymphoma
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
Hanzhou, ZhejiangAges 18–75 - NCT04300998Recruiting
CAR-T therapy study for older adults
This study looks at how well CAR-T cell therapy works and how safely it can be given to older adults. It is for people whose cancer or related blood condition has come back or did not respond, and who are receiving a standard (commercial) CAR-T product.
New York, New YorkAges 60 years+ - NCT06784167Recruiting
Vaccine response after CAR-T for myeloma and lymphoma
This study looks at how well vaccines work in people with multiple myeloma or certain lymphomas after they receive CAR-T cell therapy. It aims to help doctors understand the best way to revaccinate patients to protect against preventable diseases.
Portland, OregonAges 18 years+ - NCT06458439RecruitingPhase 2
Epcoritamab with CAR T cells for large B-cell lymphoma
This trial tests a combination of two immune therapies—epcoritamab (a bispecific antibody) and CAR T cells—for people with large B-cell lymphoma whose cancer didn't respond to first treatment. The goal is to see if this combination works better than CAR T cells alone.
Philadelphia, PennsylvaniaAges 18 years+
Common questions
- Are there clinical trials studying CAR-T cells?
- Yes. Clin2 currently lists 489 recruiting studies that include CAR-T cells, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a CAR-T cells trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is CAR-T cells an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether CAR-T cells or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.